Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has filed its quarterly statement confirming no deviation or variation in the utilisation of ₹95 crore raised via preferential issue of 11.70 lakh convertible equity warrants on March 28, 2026. The warrants carry an exercise price of ₹812 per share. Of the total proceeds, only ₹5 crore (5.3%) has been deployed so far — ₹2.5 crore each towards working capital and subsidiary working capital funding. No funds have been used yet for product development or general corporate purposes. The statement was reviewed by the Audit Committee and taken on record by the Board of Directors on May 14, 2026.
No negative signal for shareholders — the company is compliant with Regulation 32, and fund utilisation is on track as per the original objects disclosed in the EGM explanatory statement. The low utilisation rate is expected given the recent March 2026 raise and the long-horizon nature of the stated objects.